AU2001275228A1 - Cancer treatment composition containing an anti-neoplastic agent and a pde4 inhibitor - Google Patents

Cancer treatment composition containing an anti-neoplastic agent and a pde4 inhibitor

Info

Publication number
AU2001275228A1
AU2001275228A1 AU2001275228A AU7522801A AU2001275228A1 AU 2001275228 A1 AU2001275228 A1 AU 2001275228A1 AU 2001275228 A AU2001275228 A AU 2001275228A AU 7522801 A AU7522801 A AU 7522801A AU 2001275228 A1 AU2001275228 A1 AU 2001275228A1
Authority
AU
Australia
Prior art keywords
pde4 inhibitor
neoplastic agent
cancer treatment
composition containing
treatment composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001275228A
Inventor
Stephen Thomas Davis
Inderjit Kumar Dev
Ronna Ellen Dornsife
John Gordon Gray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2001275228A1 publication Critical patent/AU2001275228A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to a method for treating cancer including administering to a mammal therapeutically effective amounts of an anti-neoplastic agent and a PDE4 inhibitor, treatment combinations containing the same as well as a method for attenuating unwanted cancer treatment side effects including myelosuppression and mucositis.
AU2001275228A 2000-06-06 2001-06-04 Cancer treatment composition containing an anti-neoplastic agent and a pde4 inhibitor Abandoned AU2001275228A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20984600P 2000-06-06 2000-06-06
US60/209,846 2000-06-06
PCT/US2001/018108 WO2001093909A2 (en) 2000-06-06 2001-06-04 Cancer treatment composition containing an anti-neoplastic agent and a pde4 inhibitor

Publications (1)

Publication Number Publication Date
AU2001275228A1 true AU2001275228A1 (en) 2001-12-17

Family

ID=22780552

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001275228A Abandoned AU2001275228A1 (en) 2000-06-06 2001-06-04 Cancer treatment composition containing an anti-neoplastic agent and a pde4 inhibitor

Country Status (7)

Country Link
EP (1) EP1289557B1 (en)
JP (1) JP2003535148A (en)
AT (1) ATE332708T1 (en)
AU (1) AU2001275228A1 (en)
DE (1) DE60121440T2 (en)
ES (1) ES2267778T3 (en)
WO (1) WO2001093909A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2322601A1 (en) 2000-12-06 2011-05-18 Anthrogenesis Corporation Method of collecting placental stem cells
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
EP2338983B1 (en) 2001-02-14 2015-10-07 Anthrogenesis Corporation Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells
CN1537018A (en) * 2001-05-23 2004-10-13 田边制药株式会社 Therapeutic compositions for repairing chondropathy
US20040146561A1 (en) * 2001-05-23 2004-07-29 Naoki Sakurai Compositions for promoting healing of bone fracture
BRPI0117198B1 (en) * 2001-12-14 2018-03-13 Merck Serono S.A. USES OF COMPOSITION UNDERSTANDING A SELECTIVE INHIBITOR OF A PHOSPHODIESTERASE ISOFORM 4
US7682803B2 (en) 2005-10-13 2010-03-23 Anthrogenesis Corporation Immunomodulation using placental stem cells
MXPA04009997A (en) * 2002-04-12 2004-12-13 Celgene Corp Modulation of stem and progenitor cell differentiation, assays, and uses thereof.
KR20050086780A (en) 2002-11-26 2005-08-30 안트로제네시스 코포레이션 Cytotherapeutics, cytotherapeutic units and methods for treatments using them
US7470538B2 (en) 2002-12-05 2008-12-30 Case Western Reserve University Cell-based therapies for ischemia
EP1587512A2 (en) * 2003-01-14 2005-10-26 ALTANA Pharma AG Pde4 inhibitors for the treatment of neoplasms of lymphoid cells
WO2006040645A1 (en) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma
CN101389754A (en) 2005-12-29 2009-03-18 人类起源公司 Co-culture of placental stem cells and stem cells from a second source
CN101395266B (en) 2005-12-29 2018-06-15 人类起源公司 placental stem cell populations
EP2630959A1 (en) 2007-02-12 2013-08-28 Anthrogenesis Corporation Treatment of inflammatory diseases using placental stem cells
US9200253B1 (en) 2007-08-06 2015-12-01 Anthrogenesis Corporation Method of producing erythrocytes
KR20210127819A (en) 2007-09-28 2021-10-22 안트로제네시스 코포레이션 Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
KR20210010648A (en) 2008-08-20 2021-01-27 안트로제네시스 코포레이션 Improved cell composition and methods of making the same
EP2367932B1 (en) 2008-11-19 2019-06-12 Celularity, Inc. Amnion derived adherent cells
WO2011094181A1 (en) 2010-01-26 2011-08-04 Anthrogenesis Corporation Treatment of bone-related cancers using placental stem cells
CN107699541A (en) 2010-04-07 2018-02-16 人类起源公司 Use the angiogenesis of placenta stem-cell
KR20200077613A (en) 2010-07-13 2020-06-30 안트로제네시스 코포레이션 Methods of generating natural killer cells
WO2012092485A1 (en) 2010-12-31 2012-07-05 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory rna molecules
ES2707579T3 (en) 2011-06-01 2019-04-04 Celularity Inc Pain treatment using placental cytoblast
WO2013188138A1 (en) * 2012-06-11 2013-12-19 The Regents Of The University Of California Inhibitors of hippo-yap signaling pathway
JP2016506968A (en) 2013-02-05 2016-03-07 アントフロゲネシス コーポレーション Placenta-derived natural killer cells
US11052101B2 (en) 2019-03-25 2021-07-06 National Guard Health Affairs Methods for treating cancer using purine analogs by depleting intracellular ATP

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK122199A3 (en) * 1997-03-18 2000-12-11 Basf Ag Methods and compositions for modulating responsiveness to corticosteroids
AU2108299A (en) * 1998-01-08 1999-07-26 University Of Virginia Patent Foundation A2A adenosine receptor agonists
CA2325080A1 (en) * 1998-03-28 1999-10-07 The Regents Of The University Of California Dfmo and sulindac combination in cancer chemoprevention
US6399649B1 (en) * 1998-09-24 2002-06-04 Boston Medical Center Corporation Compositions and methods for the treatment of chronic lymphocytic leukemia
WO2001078651A2 (en) * 2000-04-12 2001-10-25 Cell Pathways, Inc. Method for treating neoplasmin with topoisomase i inhibitor
EP1188438A1 (en) * 2000-09-15 2002-03-20 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production

Also Published As

Publication number Publication date
EP1289557A2 (en) 2003-03-12
JP2003535148A (en) 2003-11-25
WO2001093909A2 (en) 2001-12-13
ATE332708T1 (en) 2006-08-15
ES2267778T3 (en) 2007-03-16
EP1289557B1 (en) 2006-07-12
DE60121440T2 (en) 2007-06-28
DE60121440D1 (en) 2006-08-24
WO2001093909A3 (en) 2002-12-05

Similar Documents

Publication Publication Date Title
AU2001275228A1 (en) Cancer treatment composition containing an anti-neoplastic agent and a pde4 inhibitor
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
MXPA04006039A (en) Methods for the treatment of peripheral neural and vascular ailments.
WO2002072031A3 (en) Substituted tetracycline compounds as synergistic antifungal agents
WO2005046618A3 (en) Methods of treating eczema
WO2004030627A3 (en) Synergistic methods and compositions for treating cancer
AU2713500A (en) Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
AU3419995A (en) Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
WO1999005096A3 (en) Urokinase inhibitors
AU3268997A (en) Chelating agents and their metal chelates for treating free radicals induced conditions
EP1392328A4 (en) Cancer therapy
AU5170400A (en) Topical application of muscarinic and opioid agents for treatment of tinnitus
WO2003013554A3 (en) Aromatase inhibitors from broussonetia papyrifera
HK1025036A1 (en) Novel cryptophycin derivatives as anti-neoplastic agents
AU6178198A (en) Method of treating a tumor
WO2002039994A3 (en) Methods for the treatment and prevention of urinary stone disease
AU8020698A (en) Use of glucosamine and glucosamine derivatives for quick alleviation of itching or localized pain
CA2408541A1 (en) Treating eczema and/or psoriasis
WO2002036129A3 (en) Topical treatment of mastalgia with arometese inhibitors such as androstendione
WO2002098362A3 (en) Use of rank antagonists to treat cancer
AP9801261A0 (en) Farnesyl transferase inhibitors in combination with HMG COA reductase inhibitors for the treatment of cancer.
WO2002062334A3 (en) Cancer chemopreventative compounds and compositions and methods of treating cancers
WO2002041831A3 (en) Inositol derivatives for increasing chloride secretion and inhibiting inflammation
AU2196297A (en) Methods of treating or preventing interstitial cystitis
WO2003053365A3 (en) Syn3 compositions and methods